VivoSim Labs, Inc. (VIVS) - Net Assets
Based on the latest financial reports, VivoSim Labs, Inc. (VIVS) has net assets worth $-2.35 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.85 Million) and total liabilities ($6.19 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See VivoSim Labs, Inc. (VIVS) balance sheet quality index to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-2.35 Million |
| % of Total Assets | -60.98% |
| Annual Growth Rate | N/A |
| 5-Year Change | -103.64% |
| 10-Year Change | -101.76% |
| Growth Volatility | 71.96 |
VivoSim Labs, Inc. - Net Assets Trend (2011–2026)
This chart illustrates how VivoSim Labs, Inc.'s net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market value of VivoSim Labs, Inc..
Annual Net Assets for VivoSim Labs, Inc. (2011–2026)
The table below shows the annual net assets of VivoSim Labs, Inc. from 2011 to 2026. Also explore VIVS net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2026-03-31 | $-1.10 Million | -110.47% |
| 2025-03-31 | $10.49 Million | +191.36% |
| 2024-03-31 | $3.60 Million | -76.51% |
| 2023-03-31 | $15.33 Million | -49.26% |
| 2022-03-31 | $30.21 Million | -22.93% |
| 2021-03-31 | $39.20 Million | +47.18% |
| 2020-03-31 | $26.63 Million | -26.63% |
| 2019-03-31 | $36.30 Million | -18.59% |
| 2018-03-31 | $44.59 Million | -28.50% |
| 2017-03-31 | $62.36 Million | +0.29% |
| 2016-03-31 | $62.18 Million | +27.69% |
| 2015-03-31 | $48.70 Million | +0.85% |
| 2014-03-31 | $48.28 Million | +1010.50% |
| 2013-03-31 | $-5.30 Million | -82539.86% |
| 2011-03-31 | $-6.42K | -- |
Equity Component Analysis
This analysis shows how different components contribute to VivoSim Labs, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 35581425800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.00K | % |
| Other Components | $354.90 Million | % |
| Total Equity | $-1.10 Million | 100.00% |
VivoSim Labs, Inc. Competitors by Market Cap
The table below lists competitors of VivoSim Labs, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PROSPECT RIDGE RESOURCES
F:0ED
|
$3.47 Million |
|
Omnia Metals Group Ltd
AU:OM1
|
$3.47 Million |
|
Centogene N.V.
NASDAQ:CNTGF
|
$3.48 Million |
|
Forterra PLC
LSE:FORT
|
$3.48 Million |
|
Co-Diagnostics, Inc. Common Stock
NASDAQ:CODX
|
$3.47 Million |
|
Alvo Minerals Ltd
AU:ALV
|
$3.45 Million |
|
Pool Safe Inc
V:POOL
|
$3.45 Million |
|
Fancy Wood Industries Public Company Limited
BK:FANCY
|
$3.45 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in VivoSim Labs, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 10,492,000 to -1,099,000, a change of -11,591,000 (-110.5%).
- Net loss of 13,843,000 reduced equity.
- New share issuances of 4,808,000 increased equity.
- Other factors decreased equity by 2,556,000.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-13.84 Million | -1259.6% |
| Share Issuances | $4.81 Million | +437.49% |
| Other Changes | $-2.56 Million | -232.58% |
| Total Change | $- | -110.47% |
Book Value vs Market Value Analysis
This analysis compares VivoSim Labs, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-03-31 | $-0.02 | $0.26 | x |
| 2013-03-31 | $-29.50 | $0.26 | x |
| 2014-03-31 | $158.44 | $0.26 | x |
| 2015-03-31 | $146.73 | $0.26 | x |
| 2016-03-31 | $165.71 | $0.26 | x |
| 2017-03-31 | $153.09 | $0.26 | x |
| 2018-03-31 | $99.78 | $0.26 | x |
| 2019-03-31 | $75.50 | $0.26 | x |
| 2020-03-31 | $49.33 | $0.26 | x |
| 2021-03-31 | $68.15 | $0.26 | x |
| 2022-03-31 | $41.65 | $0.26 | x |
| 2023-03-31 | $21.11 | $0.26 | x |
| 2024-03-31 | $4.73 | $0.26 | x |
| 2025-03-31 | $7.17 | $0.26 | x |
| 2026-03-31 | $-0.42 | $0.26 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently VivoSim Labs, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -10567.18%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-72.35%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-147.18K |
| 2013 | 0.00% | -3638.51% | 0.07x | 0.00x | $-43.02 Million |
| 2014 | -53.53% | -6820.05% | 0.01x | 1.04x | $-30.68 Million |
| 2015 | -61.78% | -5268.30% | 0.01x | 1.10x | $-34.95 Million |
| 2016 | -62.04% | -2601.15% | 0.02x | 1.09x | $-44.79 Million |
| 2017 | -61.65% | -908.91% | 0.06x | 1.11x | $-44.68 Million |
| 2018 | -78.06% | -756.09% | 0.09x | 1.12x | $-39.26 Million |
| 2019 | -73.38% | -861.70% | 0.08x | 1.12x | $-30.26 Million |
| 2020 | -70.26% | -852.00% | 0.08x | 1.07x | $-21.37 Million |
| 2021 | -42.93% | 0.00% | 0.00x | 1.02x | $-20.75 Million |
| 2022 | -37.90% | -763.20% | 0.05x | 1.10x | $-14.47 Million |
| 2023 | -112.59% | -4664.59% | 0.02x | 1.33x | $-18.79 Million |
| 2024 | -407.41% | -13459.63% | 0.02x | 1.76x | $-15.03 Million |
| 2025 | -23.71% | -1727.78% | 0.01x | 1.40x | $-3.54 Million |
| 2026 | 0.00% | -10567.18% | 0.02x | 0.00x | $-13.73 Million |
Industry Comparison
This section compares VivoSim Labs, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $249,490,347
- Average return on equity (ROE) among peers: -108.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| VivoSim Labs, Inc. (VIVS) | $-2.35 Million | 0.00% | N/A | $3.47 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $120.41 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.57 Billion |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $1.25 Million | -621.32% | 5.21x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.34 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $4.73 Billion |
About VivoSim Labs, Inc.
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models. The company also provides liver toxicology predictive screening and research services, as well as… Read more